ArticleAnnals of clinical and translational neurology2023

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.

Ho Jin Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.